Sections
Title | Starting Page | Number of Pages |
---|
1 Table of Contents | 4 | 5 |
1.1 List of Tables | 6 | 1 |
1.2 List of Figures | 7 | 2 |
2 Introduction | 9 | 34 |
2.1 Disease Overview | 9 | 1 |
2.2 Classification | 9 | 1 |
2.3 Symptoms | 10 | 1 |
2.4 Etiology | 10 | 1 |
2.5 Pathophysiology | 11 | 2 |
2.6 Epidemiology | 13 | 1 |
2.7 Prognosis | 13 | 1 |
2.8 Co-morbidities and Complications | 14 | 1 |
2.9 Diagnosis | 15 | 2 |
2.10 Assessing Treatment Effectiveness | 17 | 1 |
2.11 Treatment | 17 | 2 |
2.11.1 Non-insulin T2DM Therapies | 19 | 1 |
2.11.1.1 Biguanides | 19 | 1 |
2.11.1.2 Sulfonylureas and Meglitinides | 19 | 1 |
2.11.1.3 Thiazolidinediones | 20 | 1 |
2.11.1.4 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Dipeptidyl Peptidase 4 (DPP-4) Inhibitors | 20 | 1 |
2.11.1.5 Sodium Glucose Linked Transporter-2 (SGLT-2) Inhibitors | 21 | 1 |
2.11.1.6 Other Non-insulin Therapies | 21 | 1 |
| 21 | 1 |
2.11.1.6.2 Bile Acid Sequestrants | 21 | 1 |
2.11.2 Insulin T2DM Therapies | 22 | 2 |
2.12 Treatment Segments | 24 | 1 |
2.12.1 Non-insulin therapies | 24 | 1 |
2.12.1.1 Metformin monotherapy versus placebo | 24 | 1 |
2.12.1.2 Immediate-release metformin versus extended-release metformin either as monotherapies or in combination with other oral antidiabetic agents | 25 | 1 |
2.12.1.3 Metformin monotherapy versus glyburide monotherapy versus metformin in combination with glyburide | 26 | 2 |
2.12.1.4 Actos (pioglitazone) versus placebo as monotherapy | 28 | 2 |
2.12.1.5 Byetta (exenatide) versus Bydureon (exenatide) either as monotherapies or in combination with oral antidiabetic drugs | 30 | 1 |
2.12.1.6 Victoza (liraglutide) versus Tanzeum (albiglutide) in combination with oral antidiabetic drugs | 31 | 2 |
2.12.1.7 Trulicity (dulaglutide) versus Victoza (liraglutide) in combination with metformin | 33 | 1 |
2.12.1.8 Januvia (sitagliptin) versus glipizide as add-on therapy to metformin | 33 | 1 |
2.12.1.9 Galvus (vildagliptin) versus Actos (pioglitazone) as add-on therapy to metformin | 34 | 2 |
2.12.1.10 Onglyza (saxagliptin) versus Forxiga (dapagliflozin) versus Onglyza in combination with Forxiga as add-on therapies to metformin | 36 | 1 |
2.12.1.11 Jardiance (empagliflozin), Tradjenta (linagliptin) and Glyxambi (empagliflozin and linagliptin) as monotherapies or as add-on therapies to metformin | 37 | 1 |
2.12.1.12 Invokana (canagliflozin) versus glimepiride as add-on therapy to metformin | 38 | 1 |
2.12.2 Insulin Therapies | 39 | 1 |
2.12.2.1 Lantus (insulin glargine) versus Levemir (insulin detemir) as add-on therapy to glucose-lowering drugs | 39 | 1 |
2.12.2.2 Lantus (insulin glargine) versus Toujeo (insulin glargine) as add-on therapies to oral antidiabetic drugs or meal-time insulin | 40 | 1 |
2.12.2.3 Tresiba (insulin degludec) versus Lantus (insulin glargine) as add-on therapy to oral antidiabetic drugs | 41 | 2 |
3 Marketed Products | 43 | 27 |
3.1 Overview | 43 | 1 |
3.2 Biguanides | 44 | 1 |
3.2.1 Metformin | 44 | 1 |
3.3 Sulfonylureas | 45 | 2 |
3.4 Thiazolidinediones | 47 | 1 |
3.4.1 Pioglitazone | 47 | 1 |
3.5 GLP-1 receptor agonists | 48 | 1 |
3.5.1 Byetta (exenatide) | 48 | 1 |
3.5.2 Bydureon (exenatide) | 49 | 1 |
3.5.3 Victoza (liraglutide) | 50 | 1 |
3.5.4 Lyxumia (lixisenatide) | 51 | 2 |
3.5.5 Tanzeum (albiglutide) | 53 | 1 |
3.5.6 Trulicity (dulaglutide) | 54 | 1 |
3.6 DPP-4 Inhibitors | 55 | 1 |
3.6.1 Januvia/Glactiv (sitagliptin) | 55 | 1 |
3.6.2 Galvus (vildagliptin) | 56 | 1 |
3.6.3 Onglyza (saxagliptin) | 57 | 1 |
3.6.4 Trazenta (linagliptin) | 58 | 1 |
3.6.5 Zafatek (trelagliptin succinate) | 59 | 1 |
3.6.6 Marizev (omarigliptin) | 60 | 1 |
3.7 SGLT-2 Inhibitors | 61 | 1 |
3.7.1 Forxiga (dapagliflozin) | 61 | 1 |
3.7.2 Invokana (canagliflozin) | 62 | 1 |
3.7.3 Jardiance (empagliflozin) | 63 | 1 |
3.8 Insulin Therapies | 63 | 1 |
3.8.1 Lantus (insulin glargine) | 63 | 1 |
3.8.2 Levemir (insulin detemir) | 64 | 1 |
3.8.3 Tresiba (insulin degludec) | 65 | 1 |
3.8.4 Toujeo/ Lantus XR (insulin glargine) | 66 | 1 |
3.9 Marketed Products Heat Maps | 67 | 3 |
4 Pipeline | 70 | 29 |
4.1 Overview | 70 | 1 |
4.2 Pipeline Distribution by Stage of Development, Molecule Type and Program Type | 71 | 1 |
4.3 Pipeline Distribution by Molecular Target | 72 | 7 |
4.4 Clinical Trial Landscape | 79 | 1 |
4.4.1 Clinical Trial Failure Rates | 79 | 5 |
4.4.2 Clinical Trial Duration | 84 | 3 |
4.4.3 Clinical Trial Size | 87 | 3 |
4.4.4 Clinical Trial Metrics Analysis | 90 | 2 |
4.5 Promising Pipeline Molecules | 92 | 1 |
4.5.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) Novo Nordisk | 92 | 2 |
4.5.2 ITCA 650 Intarcia Therapeutics | 94 | 2 |
4.5.3 Ertugliflozin Pfizer | 96 | 2 |
4.6 Pipeline Products Heat Map | 98 | 1 |
5 Market Forecast to 2021 | 99 | 14 |
5.1 Geographical Markets | 99 | 1 |
5.2 Asia-Pacific Markets | 99 | 3 |
5.3 China | 102 | 1 |
5.3.1 Treatment Usage Patterns | 102 | 1 |
5.3.2 Annual Cost of Therapy | 103 | 1 |
5.3.3 Market Size | 103 | 1 |
5.4 India | 104 | 1 |
5.4.1 Treatment Usage Patterns | 104 | 1 |
5.4.2 Annual Cost of Therapy | 105 | 1 |
5.4.3 Market Size | 106 | 1 |
5.5 Australia | 107 | 1 |
5.5.1 Treatment Usage Patterns | 107 | 1 |
5.5.2 Annual Cost of Therapy | 107 | 1 |
5.5.3 Market Size | 108 | 1 |
5.6 Japan | 109 | 1 |
5.6.1 Treatment Usage Patterns | 109 | 1 |
5.6.2 Annual Cost of Therapy | 109 | 1 |
5.6.3 Market Size | 110 | 1 |
5.7 Drivers and Barriers for the T2DM Therapeutics Market | 111 | 1 |
5.7.1 Drivers | 111 | 1 |
5.7.1.1 Increasing Aging Population and Obesity, and Growing Economy | 111 | 1 |
5.7.1.2 Increasing Awareness of T2DM | 111 | 1 |
5.7.1.3 Continued Uptake of Recently Approved Drug Classes | 111 | 1 |
5.7.1.4 Promising Late-Stage Pipeline Products can Change the Treatment Paradigm | 111 | 1 |
5.7.1.5 Enhanced Usage of Combination Therapies | 111 | 1 |
5.7.2 Barriers | 112 | 1 |
5.7.2.1 Non-pharmacological First-line Treatment | 112 | 1 |
5.7.2.2 Widespread Usage of Generic Drugs | 112 | 1 |
5.7.2.3 Poor Adherence to Treatment Regimens | 112 | 1 |
5.7.2.4 Generic Erosion Resulting From Patent Expirations | 112 | 1 |
6 Strategic Consolidations | 113 | 16 |
6.1 Licensing Deals | 113 | 6 |
6.1.1 AbbVie Collaborates with Halozyme Therapeutics to Bank on its ENHANZE Technology | 119 | 1 |
6.1.2 Janssen Collaborates with Halozyme Therapeutics to Bank on its ENHANZE Technology | 119 | 1 |
6.1.3 Emisphere Signs Licensing Agreement with Novo Nordisk to Develop Oral Formulations Targeting Metabolic Indications | 119 | 1 |
6.1.4 Amunix Announces Exclusive Agreements with Naia to Develop GLP-1 and GLP-2 XTEN Products | 120 | 1 |
6.2 Co-development Deals | 120 | 6 |
6.2.1 Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 (DUROS delivery exenatide) | 126 | 1 |
6.2.2 Merck Enters into Co-Development Agreement with Pfizer for ertugliflozin | 127 | 1 |
6.2.3 AstraZeneca Enters into Research Agreement with Inserm | 127 | 1 |
6.2.4 Intarcia Therapeutics Enters into Co-Development Agreement with Numab | 127 | 1 |
6.2.5 AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb | 128 | 1 |
7 Appendix | 129 | 38 |
7.1 All Pipeline Drugs by Phase of Development | 129 | 17 |
7.1.1 Discovery | 129 | 3 |
7.1.2 Preclinical | 132 | 8 |
7.1.3 IND/CTA-filed | 140 | 1 |
7.1.4 Phase I | 141 | 2 |
7.1.5 Phase II | 143 | 2 |
7.1.6 Phase III | 145 | 1 |
7.1.7 Pre-registration | 145 | 1 |
7.2 Market Forecasts to 2021 | 146 | 2 |
7.2.1 Asia-Pacific | 146 | 1 |
7.2.2 China | 146 | 1 |
7.2.3 India | 146 | 1 |
7.2.4 Australia | 147 | 1 |
7.2.5 Japan | 147 | 1 |
7.3 References | 148 | 12 |
7.4 Abbreviations | 160 | 2 |
7.5 Research Methodology | 162 | 4 |
7.5.1 Secondary Research | 162 | 1 |
7.5.2 Marketed Product Profiles | 163 | 1 |
7.5.3 Late-Stage Pipeline Candidates | 163 | 1 |
7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products | 163 | 1 |
7.5.4.1 Overall Pipeline | 163 | 1 |
7.5.4.2 Clinical Trials | 164 | 1 |
7.5.4.2.1 Failure Rate | 164 | 1 |
7.5.4.2.2 Clinical Trial Size | 164 | 1 |
7.5.4.2.3 Clinical Trial Duration | 164 | 1 |
7.5.4.2.4 Clinical trial Endpoint Analysis | 164 | 1 |
7.5.5 Forecasting Model | 164 | 1 |
7.5.6 Deals Data Analysis | 165 | 1 |
7.6 Contact Us | 165 | 1 |
7.7 Disclaimer | 166 | 1 |